These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27450875)

  • 1. LGE Means Better Selection of HCM Patients for Primary Prevention Implantable Defibrillators.
    Maron BJ; Maron MS
    JACC Cardiovasc Imaging; 2016 Dec; 9(12):1403-1406. PubMed ID: 27450875
    [No Abstract]   [Full Text] [Related]  

  • 2. 3.0 T magnetic resonance myocardial perfusion imaging for semi-quantitative evaluation of coronary microvascular dysfunction in hypertrophic cardiomyopathy.
    Yin L; Xu HY; Zheng SS; Zhu Y; Xiao JX; Zhou W; Yu SS; Gong LG
    Int J Cardiovasc Imaging; 2017 Dec; 33(12):1949-1959. PubMed ID: 28612277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Cardiac Magnetic Resonance Feature Tracking (CMR-FT) Analysis for Detection of Myocardial Fibrosis in Pediatric Hypertrophic Cardiomyopathy.
    Bogarapu S; Puchalski MD; Everitt MD; Williams RV; Weng HY; Menon SC
    Pediatr Cardiol; 2016 Apr; 37(4):663-73. PubMed ID: 26833321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy.
    Klopotowski M; Kukula K; Malek LA; Spiewak M; Polanska-Skrzypczyk M; Jamiolkowski J; Dabrowski M; Baranowski R; Klisiewicz A; Kusmierczyk M; Jasinska A; Jarmus E; Kruk M; Ruzyllo W; Witkowski A; Chojnowska L
    J Cardiol; 2016 Jul; 68(1):49-56. PubMed ID: 26363820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative diffusion-weighted magnetic resonance imaging in the assessment of myocardial fibrosis in hypertrophic cardiomyopathy compared with T1 mapping.
    Wu LM; Chen BH; Yao QY; Ou YR; Wu R; Jiang M; Hu J; An DA; Xu JR
    Int J Cardiovasc Imaging; 2016 Aug; 32(8):1289-97. PubMed ID: 27198892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy: comparison of diagnostic performance in myocardial fibrosis between gadobutrol and gadopentetate dimeglumine.
    Liu D; Ma X; Liu J; Zhao L; Chen H; Xu L; Sun Z; Fan Z
    Int J Cardiovasc Imaging; 2017 Aug; 33(8):1191-1200. PubMed ID: 28289991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myocardial perfusion reserve quantified by cardiac magnetic resonance imaging is associated with late gadolinium enhancement in hypertrophic cardiomyopathy.
    Tezuka D; Kosuge H; Terashima M; Koyama N; Kishida T; Tada Y; Suzuki JI; Sasano T; Ashikaga T; Hirao K; Isobe M
    Heart Vessels; 2018 May; 33(5):513-520. PubMed ID: 29168014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffuse Ventricular Fibrosis on Cardiac Magnetic Resonance Imaging Associates With Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy.
    McLELLAN AJ; Ellims AH; Prabhu S; Voskoboinik A; Iles LM; Hare JL; Kaye DM; Macciocca I; Mariani JA; Kalman JM; Taylor AJ; Kistler PM
    J Cardiovasc Electrophysiol; 2016 May; 27(5):571-80. PubMed ID: 26840595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Native T1-mapping for non-contrast assessment of myocardial fibrosis in patients with hypertrophic cardiomyopathy--comparison with late enhancement quantification.
    Małek ŁA; Werys K; Kłopotowski M; Śpiewak M; Miłosz-Wieczorek B; Mazurkiewicz Ł; Petryka-Mazurkiewicz J; Marczak M; Witkowski A
    Magn Reson Imaging; 2015 Jul; 33(6):718-24. PubMed ID: 25863138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy.
    Green JJ; Berger JS; Kramer CM; Salerno M
    JACC Cardiovasc Imaging; 2012 Apr; 5(4):370-7. PubMed ID: 22498326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of global and regional myocardial mechanics with 3-dimensional speckle tracking echocardiography and relations to hypertrophy and fibrosis in hypertrophic cardiomyopathy.
    Urbano-Moral JA; Rowin EJ; Maron MS; Crean A; Pandian NG
    Circ Cardiovasc Imaging; 2014 Jan; 7(1):11-9. PubMed ID: 24275954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of late gadolinium enhancement in end-stage hypertrophic cardiomyopathy and dilated cardiomyopathy: differential diagnosis and prediction of cardiac outcome.
    Machii M; Satoh H; Shiraki K; Saotome M; Urushida T; Katoh H; Takehara Y; Sakahara H; Ohtani H; Wakabayashi Y; Ukigai H; Tawarahara K; Hayashi H
    Magn Reson Imaging; 2014 Feb; 32(2):118-24. PubMed ID: 24315973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocardial fibrosis progression on cardiac magnetic resonance in hypertrophic cardiomyopathy.
    Choi HM; Kim KH; Lee JM; Yoon YE; Lee SP; Park EA; Lee W; Kim YJ; Cho GY; Sohn DW; Kim HK
    Heart; 2015 Jun; 101(11):870-6. PubMed ID: 25897040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of late gadolinium enhancement quantification in cardiac magnetic resonance imaging of hypertrophic cardiomyopathy with systolic dysfunction.
    Funada A; Kanzaki H; Noguchi T; Morita Y; Sugano Y; Ohara T; Hasegawa T; Hashimura H; Ishibashi-Ueda H; Kitakaze M; Yasuda S; Ogawa H; Anzai T
    Heart Vessels; 2016 May; 31(5):758-70. PubMed ID: 25820658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous contrast T1rho cardiac magnetic resonance for myocardial fibrosis in hypertrophic cardiomyopathy patients.
    Wang C; Zheng J; Sun J; Wang Y; Xia R; Yin Q; Chen W; Xu Z; Liao J; Zhang B; Gao F
    J Cardiol; 2015 Dec; 66(6):520-6. PubMed ID: 25981868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitral annular plane systolic excursion is an easy tool for fibrosis detection by late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy.
    Doesch C; Sperb A; Sudarski S; Lossnitzer D; Rudic B; Tülümen E; Heggemann F; Schimpf R; Schoenberg SO; Borggrefe M; Papavassiliu T
    Arch Cardiovasc Dis; 2015; 108(6-7):356-66. PubMed ID: 25863428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive assessment of myocardial fibrosis in patients with obstructive hypertrophic cardiomyopathy.
    Almaas VM; Haugaa KH; Strøm EH; Scott H; Smith HJ; Dahl CP; Geiran OR; Endresen K; Aakhus S; Amlie JP; Edvardsen T
    Heart; 2014 Apr; 100(8):631-8. PubMed ID: 24368281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late gadolinium enhancement is common in patients with hypertrophic cardiomyopathy and no clinical risk factors for sudden cardiac death: A single center experience.
    Lyons KS; Dixon LJ; Johnston N; Noad R; Hamilton A; McKeag N; Horan P
    Cardiol J; 2014; 21(1):29-32. PubMed ID: 23990187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of left ventricular dyssynchrony on gated myocardial perfusion SPECT analysis with extent of late gadolinium enhancement on cardiac magnetic resonance imaging in hypertrophic cardiomyopathy.
    Yuki H; Utsunomiya D; Shiraishi S; Takashio S; Sakamoto F; Tsuda N; Oda S; Kidoh M; Nakaura T; Tsujita K; Yamashita Y
    Heart Vessels; 2018 Jun; 33(6):623-629. PubMed ID: 29230571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systolic and diastolic myocardial mechanics in hypertrophic cardiomyopathy and their link to the extent of hypertrophy, replacement fibrosis and interstitial fibrosis.
    Nucifora G; Muser D; Gianfagna P; Morocutti G; Proclemer A
    Int J Cardiovasc Imaging; 2015 Dec; 31(8):1603-10. PubMed ID: 26210792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.